<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780091</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2005/04</org_study_id>
    <nct_id>NCT00780091</nct_id>
  </id_info>
  <brief_title>Optimisation of Monitoring for Clinical Research Studies</brief_title>
  <acronym>OPTIMON</acronym>
  <official_title>Evaluation of Efficacy and Cost of Two Monitoring Strategies for Public Clinical Research - OPTIMON: Optimisation of Monitoring for Clinical Research Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OPTIMON will compare the efficacy and the cost of two monitoring strategies: one based on the
      classic standards of quality assurance, and the other one being a priori &quot;optimized&quot; on the
      main scientific and regulatory principles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no validated standard of monitoring strategy for clinical research studies. Optimon
      will compare two monitoring strategies - a classical strategy based on the practices of the
      pharmaceutical industry, and an optimized strategy based on patient's risk level - on their
      ability to produce exact data, focusing on the main quality criteria: regulatory requirements
      and scientific validity of results. Optimon is a non inferiority randomized trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients' file without severe error.</measure>
    <time_frame>at end of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compounds of the main outcome, other errors, delay to get the results, costs</measure>
    <time_frame>at end of follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>classical monitoring strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>optimized monitoring strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>classical monitoring strategy</intervention_name>
    <description>intensive on-site monitoring, consistently with the pharmaceutical industry practices</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>optimized monitoring strategy</intervention_name>
    <description>optimized on-site monitoring, depending on patient's risk</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All type of patients enrolled in the eligible studies
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Research Studies: risk level A, B, or C in the Optimon risk-assessment scale,
             with or without a sponsor and the advice of an ethical committee, starting in 2008 and
             ending before the end of 2010, with a foreseen accrual of 20 patients or more,
             multicentric with at least 4 clinical sites, with a paper or electronic CRF, with the
             participating agreement of the coordinating investigator and the sponsor.

          -  Clinical sites: Sites with a foreseen accrual of 5 patients at least, with the
             participating agreement of the principal investigator.

          -  Clinical Research Units: with the label of an institution, with at least 2 years of
             experience in multicentric studies, with SOPs finalized before 2008, willing to
             participate in Optimon.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geneviève CHENE, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique du CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Liénard JL, Quinaux E, Fabre-Guillevin E, Piedbois P, Jouhaud A, Decoster G, Buyse M; European Association for Research in Oncology. Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer. Clin Trials. 2006;3(5):486-92.</citation>
    <PMID>17060222</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>August 11, 2010</last_update_submitted>
  <last_update_submitted_qc>August 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jean-Pierre LEROY / Clinical Research and Innovation Director</name_title>
    <organization>University hospital, Bordeaux</organization>
  </responsible_party>
  <keyword>optimization</keyword>
  <keyword>risk scale</keyword>
  <keyword>non inferiority</keyword>
  <keyword>cluster randomization</keyword>
  <keyword>monitoring strategies</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

